Formulation of Furosemide Dispersible Tablets for Use in Paediatrics

The East and Central African Journal of Pharmaceutical Sciences Pub Date : 2015-01-01 DOI:10.4314/ECAJPS.V18I2

V. V. Abwova, P. N. Mbeo, L. Tirop, K. Kuria

{"title":"Formulation of Furosemide Dispersible Tablets for Use in Paediatrics","authors":"V. V. Abwova, P. N. Mbeo, L. Tirop, K. Kuria","doi":"10.4314/ECAJPS.V18I2","DOIUrl":null,"url":null,"abstract":"Furosemide (4 mg) dispersible tablets tailored for paediatric patients were formulated by direct compression using granulated lactose as the filler. Combinations of superdisintergrants namely sodium starch glycolate-crospovidone, sodium starch glycolate-croscarmellose and croscarmellose-crospovidone were incorporated to form three tablet batches; with a total superdisintegrant concentration of 4% w/w per tablet. The quality of the resultant tablets was evaluated using pharmacopoeial physicochemical tests. Tablets prepared with sodium starch glycolate-crospovidone and croscarmellose-crospovidone as superdisintegrants were found to comply with all specifications for tablet quality, while those formulated with sodium starch glycolate-croscarmellose, failed both the uniformity of weight and friability tests. This study showed that low dose furosemide dispersible tablets for pediatric use can be formulated using 4% w/w combinations of sodium starch glycolate-crospovidone and croscarmellosecrospovidone as superdisintegrants. Keywords : Furosemide, dispersible tablet, pediatric, formulation, superdisintegrants","PeriodicalId":22387,"journal":{"name":"The East and Central African Journal of Pharmaceutical Sciences","volume":"38 1","pages":"61-66"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The East and Central African Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/ECAJPS.V18I2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Furosemide (4 mg) dispersible tablets tailored for paediatric patients were formulated by direct compression using granulated lactose as the filler. Combinations of superdisintergrants namely sodium starch glycolate-crospovidone, sodium starch glycolate-croscarmellose and croscarmellose-crospovidone were incorporated to form three tablet batches; with a total superdisintegrant concentration of 4% w/w per tablet. The quality of the resultant tablets was evaluated using pharmacopoeial physicochemical tests. Tablets prepared with sodium starch glycolate-crospovidone and croscarmellose-crospovidone as superdisintegrants were found to comply with all specifications for tablet quality, while those formulated with sodium starch glycolate-croscarmellose, failed both the uniformity of weight and friability tests. This study showed that low dose furosemide dispersible tablets for pediatric use can be formulated using 4% w/w combinations of sodium starch glycolate-crospovidone and croscarmellosecrospovidone as superdisintegrants. Keywords : Furosemide, dispersible tablet, pediatric, formulation, superdisintegrants

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

儿科用速尿分散片的研制

为儿科患者量身定制的速尿(4mg)分散片采用颗粒状乳糖作为填充物直接压缩配制。采用乙醇酸淀粉钠-交叉维酮、乙醇酸淀粉钠-交联卡蜜糖和交联卡蜜糖-交叉维酮的超分离剂组合组成3个批次的片剂;总超崩解剂浓度为4% w/w /片。采用药典理化试验对所制片剂的质量进行评价。以乙醇酸淀粉钠-交叉维酮和交联卡蜜酮-交叉维酮为超崩解剂制备的片剂均符合片剂质量标准，而以乙醇酸淀粉钠-交联卡蜜酮配制的片剂均不合格。本研究表明，采用4% w/w的乙醇酸淀粉钠-交叉聚维酮和交叉聚维酮的组合作为超崩解剂，可配制儿童用低剂量呋塞米分散片。关键词:速尿，分散片，儿童，配方，超崩解剂

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

The East and Central African Journal of Pharmaceutical Sciences

自引率

0.00%

发文量